3 JANUARY 2024

EQUITY RESEARCH - COMPANY REPORT

MASTER STYLE

MASTER TB

Profit sharing is coming in 2024

- Operating hours to rise to new high in 4Q23, supported by the high season and full-quarter realization of new operating beds.
- Starting to recognize profit sharing from new investments.
- Maintain BUY with a solid net profit growth outlook and strong balance sheet.

4Q23 profit to peak, supported by longer operating hours

We expect MASTER's 4Q23 net profit to rise to a new high of THB115m (+14.8% q-q, +45.6% y-y) due to the full-quarter realization of new operating beds. Normally, 4Q is a high season. According to the latest data, customer numbers continued to rise in October-November before weakening in December, since it is a holiday season. We anticipate its 4Q operating hours to grow by 8.3% y-y to 13,632 hours. Hence, we expect its 4Q23 total revenue to grow by 6.2% q-q and 7.9% y-y to reach a record high at THB509m.

Starting profit sharing recognition in 4Q23 onward

Even though MASTER will recognize depreciation expenses of THB8m-10m from the improvement expenses for its buildings, profit sharing from the two new businesses, Wind Clinic and Kin Corporation, should fully offset them. Since the number of doctors remains at 45 as in 3Q23, we expect the 4Q23 gross margin to remain high at 58.1%, close to 3Q23 but higher than 55.5% in 4Q22 due to increased operating leverage. Assuming in-line results, 2023 net profit would hit another record high of THB367m (+22% y-y).

Expect 2024 profit growth to jump by 46%

We maintain our bullish view of MASTER's 2024 growth outlook due to 1) organic drivers, such as the full-year realization of its new operating beds; and 2) inorganic drivers, such as the realization of profit sharing from the ten companies that MASTER announced 35-40% stakes in. We assume 2024-25 profit sharing of THB105m and THB112m, up from THB10m in 2023, representing roughly 19.6% and 18.5% of the 2024-25E net profit, respectively. Therefore, we expect a 2024-25 net profit of THB536m (+46% y-y) and THB607m (+13% y-y), respectively.

Maintain BUY with solid growth outlook and strong balance sheet

We retain our BUY call and 2024 TP of THB71, based on 35x 2024E P/E. Our target is derived from the existing business valued at THB59/shr and the ten new investments valued at THB12/shr. We project its 2023-24 current ratio to be high at 9x and 3.2x, while we project a low D/E ratio at 0.2x. Meanwhile, ROE should stand at 22.5% in 2023, down from 2022, due to increased equity after its IPO.



Sureeporn Teewasuwet Fundamental Investment Analyst on Securities; License no. 040694 sureeporn.t@fssia.com, +66 2646 9972



TARGET PRICE	THB71.00
CLOSE	THB58.00
UP/DOWNSIDE	+22.4%
PRIOR TP	THB71.00
CHANGE IN TP	UNCHANGED
TP vs CONSENSUS	-11.6%

KEY STOCK DATA

YE Dec (THB m)	2022	2023E	2024E	2025E
Revenue	1,483	1,883	2,216	2,517
Net profit	301	367	536	607
EPS (THB)	1.58	1.39	2.03	2.30
vs Consensus (%)	-	(2.5)	1.8	0.1
EBITDA	422	529	659	750
Recurring net profit	301	367	536	607
Core EPS (THB)	1.58	1.39	2.03	2.30
Chg. In EPS est. (%)	-	-	-	-
EPS growth (%)	(1.7)	(12.1)	45.8	13.3
Core P/E (x)	36.6	41.7	28.6	25.2
Dividend yield (%)	0.5	1.2	1.7	-
EV/EBITDA (x)	26.6	25.7	22.8	19.6
Price/book (x)	27.3	5.4	4.9	4.5
Net debt/Equity (%)	51.7	(59.1)	(10.1)	(16.9)
ROE (%)	105.5	22.5	17.9	18.5
Mar-23 90 80 70 60 50 40 30 20 10 0 (THB) Mar	Jun-23	Sep-23	Dec-23	 2500 2000 1500 1000 500 0 (%)
Share price performant	ce	1 Month	3 Month	12 Month
Absolute (%)		7.4	(6.1)	n/a
Relative to country (%)		4.0	(3.6)	n/a
Mkt cap (USD m)				448
3m avg. daily turnover	(USD m)			2.3
Free float (%)				0
Major shareholder		Masch	amadol fai	mily (68%)
12m high/low (THB)			8	3.18/41.50
Issued shares (m)				264.00

Sources: Bloomberg consensus; FSSIA estimates

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Investment thesis

We expect Thailand's cosmetic surgery market to grow by 9.7% CAGR in 2023-30, close to global cosmetic surgery markets. Additionally, the medical tourism trend should support surgery hospitals in Thailand to have a higher revenue mix from international customers, which would, in turn, support future growth.

MASTER has several strengths. It has earned a good reputation and has become well-known over the past ten years. Given the experience of Dr. Raweewat Maschamadol and other renowned doctors, MASTER has gained customer trust, leading to referrals and positive reviews on social media. It has also expanded and invested in other businesses to further its long-term growth.

Company profile

MASTER is in the cosmetic surgery hospital business under Masterpiece Hospital. Established in 2012, it has 17 operating beds and offers one-stop cosmetic surgery services. MASTER earns revenue from four services, including surgery, skin, hair treatment, and aftercare, with surgery contributing the highest revenue of 81% of total revenue.

www.masterpiecehospital.com

Catalysts

2024 potential growth drivers include 1) more surgery customers; 2) a higher utilization rate for operating beds, which would drive operating leverage; and 3) the realization of profit and synergies from M&As.

Risks to our call

Downside risks to our P/E-based TP include 1) increased competition, 2) a pandemic that results in a lockdown, 3) lower-than-expected utilization rate of new operating beds, 4) higher-than-expected doctor costs and expenses, and 5) a loss contribution from the acquired units.

Event calendar

Date	Event
February 2024	4Q23 results announcement
March 2024	4Q23 analyst meeting

Principal activities (revenue, 2022)




■ Others - 2.1 %

Source: Master Style

Major shareholders

Others - 32.0 %

Maschamadol family - 68.0 %



Key assumptions

Source: Master Style

	2023E	2024E	2025E
Total OR rooms (no.)	17	17	17
Capacity hours (hours)	64,605	88,330	88,330
Operating hours (hours)	48,147	54,272	58,866
Utilization rate (%)	74.5	61.4	66.6

Source: FSSIA estimates

Earnings sensitivity

- For every 5% increase in revenue, we estimate 2024 net profit to rise by 3.9%, and vice versa, all else being equal.
- For every 0.5% increase in GPM, we estimate 2024 net profit to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in SG&A, we estimate 2024 net profit to fall by 3.5%, and vice versa, all else being equal.

Source: FSSIA estimates




Exhibit 1: 4Q23 earnings preview

	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23E	Chan	ge
	(THB m)	(q-q%)	(y-y%)							
Total revenue	238	372	401	471	436	459	479	509	6.2	7.9
Costs	102	163	167	210	182	204	200	213	6.4	1.7
Gross profit	136	209	234	262	253	255	279	296	6.0	12.9
SG&A	68	106	128	161	162	158	160	169	5.3	4.7
Operating profit	71	104	108	103	94	106	128	137	6.4	33.0
Profit sharing	0	0	0	0	0	0	0	10	nm	nm
Interest expense	2	2	2	3	3	4	4	4	(0.3)	0.4
Tax expense	14	21	21	21	19	21	25	29	14.0	39.2
Reported net profit	55	82	85	79	72	81	100	115	14.8	45.6
Core profit	55	82	85	79	72	81	100	115	14.8	45.6
Key Ratios (%)									(ppt)	(ppt)
Gross margin	57.3	56.2	58.4	55.5	58.2	55.5	58.2	58.1	(0.1)	2.6
SG&A to sales	28.5	28.5	31.8	34.2	37.2	34.3	33.5	33.2	(0.3)	(1.0)
Operating margin	29.7	28.1	27.0	21.8	21.5	23.1	26.8	26.9	0.1	5.1
Net margin	23.1	22.1	21.2	16.7	16.4	17.7	20.8	22.5	1.7	5.8
Core margin	23.1	22.1	21.2	16.7	16.4	17.7	20.8	22.5	1.7	5.8
Operating Statistics										
Revenue breakdown (THB m)										
Surgery	192	293	320	389	340	364	387	410	6.0	5.6
Skin	15	26	28	38	42	34	33	36	10.0	(4.4)
Hair treatment	15	24	29	21	28	32	31	34	7.7	57.8
Aftercare	12	19	13	18	18	18	17	17	4.0	(1.5)
Other	4	10	11	6	8	11	11	12	0.3	78.8
Revenue proportion (%)										
Surgery	80.6	78.8	79.8	82.4	78.0	79.2	80.8	80.7	(0.1)	(1.8)
Skin	6.2	6.9	6.9	8.0	9.6	7.5	6.8	7.0	0.2	(0.9)
Hair treatment	6.3	6.6	7.3	4.5	6.4	6.9	6.5	6.6	0.1	2.1
Aftercare	5.2	5.1	3.3	3.7	4.1	3.9	3.5	3.4	(0.1)	(0.3)
Other	1.8	2.6	2.7	1.4	1.9	2.4	2.4	2.3	(0.1)	0.9


Sources: MASTER; FSSIA estimates

Exhibit 2: Quarterly operating hours and utilization rate



Sources: MASTER, FSSIA estimates


Exhibit 3: Quarterly total revenue and growth



Sources: MASTER, FSSIA estimates


FINANSIA

Exhibit 4: Quarterly gross margin



Sources: MASTER, FSSIA estimates

Exhibit 6: Yearly operating hours and utilization rate




Sources: MASTER, FSSIA estimates

Exhibit 8: Yearly gross margin and SG&A to sales




Sources: MASTER, FSSIA estimates

Exhibit 5: Quarterly net profit and net margin




Sources: MASTER, FSSIA estimates

Exhibit 7: Yearly total revenue and growth



Sources: MASTER, FSSIA estimates

Exhibit 9: Yearly net profit and growth



Sources: MASTER, FSSIA estimates

FINANSIA

Exhibit 10: Key assumptions for MASTER

	Actual		- Forecast	<i>-</i> -		Growth	
	2022	2023E	2024E	2025E	2023E	2024E	2025E
	(THB m)	(THB m)	(THB m)	(THB m)	(%)	(%)	(%)
Total revenue	1,483	1,883	2,216	2,517	27.0	17.7	13.6
Costs	641	800	920	1,040	24.8	14.9	13.0
Gross profit	841	1,083	1,296	1,478	28.7	19.7	14.0
SG&A expense	463	650	731	831	40.3	12.6	13.6
Interest expense	9	14	14	13	53.5	(1.4)	(5.4)
Profit sharing	0	10	105	112	nm	950.0	6.7
Reported net profit	301	367	536	607	22.1	45.8	13.3
Core profit	301	367	536	607	22.1	45.8	13.3
Key ratios (%)							
Total revenue growth	124.8	27.0	17.7	13.6			
Net profit growth	84.8	22.1	45.8	13.3			
Core profit growth	114.9	22.1	45.8	13.3			
Gross margin	56.7	57.5	58.5	58.7	0.7	1.0	0.2
SG&A to sales	31.2	34.5	33.0	33.0	3.3	(1.5)	0.0
Net margin	20.3	19.5	22.7	23.3	(0.8)	3.2	0.6
Core margin	20.3	19.5	22.7	23.3	(0.8)	3.2	0.6
Operating statistics							
Total OR rooms (no.)	7	17	17	17	142.9	0.0	0.0
Capacity hours (hours)	40,880	64,605	88,330	88,330	58.0	36.7	0.0
Operating hours (hours)	38,345	48,147	54,272	58,866	25.6	12.7	8.5
Utilization rate (%)	93.8	74.5	61.4	66.6			
Revenue breakdown (THB m)							
Surgery	1,194	1,501	1,777	2,024	25.8	18.4	13.9
Skin	106	144	171	197	36.8	18.5	15.4
Hair treatment	90	125	148	167	38.6	18.5	13.3
Aftercare	62	70	76	82	12.1	8.2	8.1
Others	31	42	45	47	36.8	5.0	5.0
Revenue proportion (%)							
Surgery	80.5	79.7	80.2	80.4			
Skin	7.1	7.7	7.7	7.8			
Hair treatment	6.1	6.6	6.7	6.6			
Aftercare	4.2	3.7	3.4	3.2			
			÷				

Source: FSSIA estimates

Financial Statements

Master Style

Profit and Loss (THB m) Year Ending Dec	2021	2022	2023E	2024E	20255
Revenue	660	1,483	1,883	2,216	2,51
Cost of goods sold	(312)	(641)	(800)	(920)	(1,040
Gross profit	348	841	1,083	1,296	1,478
Other operating income	31	8	31	13	13
Operating costs	(167)	(463)	(650)	(731)	(831
Operating EBITDA	242	422	529	659	750
Depreciation	(31)	(35)	(65)	(80)	(90
Goodwill amortisation	0	0	0	Ó	Ì.
Operating EBIT	211	386	464	578	660
Net financing costs	(7)	(9)	(14)	(14)	(13
Associates	0	0	10	105	112
Recurring non-operating income	0	0	10	105	112
Non-recurring items	0	0	0	0	(
Profit before tax	204	377	460	670	758
Tax	(42)		(93)		(152
		(76)	. ,	(134)	•
Profit after tax	163	301	367	536	607
Minority interests	-	-	-	-	
Preferred dividends	-	-	-	-	
Other items	-	-	-	-	
Reported net profit	163	301	367	536	607
Non-recurring items & goodwill (net)	0	0	0	0	(
Recurring net profit	163	301	367	536	60
Per share (THB)					
Recurring EPS *	1.61	1.58	1.39	2.03	2.3
Reported EPS	1.61	1.58	1.39	2.03	2.3
DPS	0.36	0.30	0.70	1.01	0.0
Diluted shares (used to calculate per share data)	101	190	264	264	26
Growth					
Revenue (%)	7.9	124.8	27.0	17.7	13.0
Operating EBITDA (%)	27.0	73.9	25.6	24.4	13.8
Operating EBIT (%)	26.1	82.7	20.2	24.6	14.0
Recurring EPS (%)	26.6	(1.7)	(12.1)	45.8	13.3
Reported EPS (%)	26.6	(1.7)	(12.1)	45.8	13.3
Operating performance		. ,	. ,		
Gross margin inc. depreciation (%)	52.7	56.7	57.5	58.5	58.7
Gross margin exc. depreciation (%)	57.4	59.1	61.0	62.1	62.3
Operating EBITDA margin (%)	36.8	28.4	28.1	29.7	29.8
Operating EBIT margin (%)	32.1	26.1	24.6	26.1	26.2
	24.7		19.5	24.2	20.
Net margin (%)		20.3			
Effective tax rate (%)	20.4	20.2	20.2	20.0	20.0
Dividend payout on recurring profit (%)	22.1	18.9	50.0	50.0	
nterest cover (X)	30.6	42.4	33.9	49.5	59.
Inventory days	30.1	26.8	31.8	30.7	31.
Debtor days	1.2	0.9	1.0	0.9	0.9
Creditor days	40.9	34.7	34.9	30.7	31.
Operating ROIC (%)	104.0	115.1	61.3	57.9	66.
ROIC (%)	93.2	82.1	42.3	27.3	21.
ROE (%)	77.0	105.5	22.5	17.9	18.
ROA (%)	30.9	39.9	17.4	15.4	16.0
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2021	2022	2023E	2024E	2025
Surgery	527	1,194	1,501	1,777	2,024
Skin	39	106	144	171	19
Hair treatment	23	90	125	148	16

Financial Statements Master Style

Aaster Style					
Cash Flow (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
ecurring net profit	163	301	367	536	607
epreciation	31	35	65	80	90
sociates & minorities	0	0	0	0	(
ther non-cash items	46	0	(10)	(105)	(112
hange in working capital	(21)	(100)	9	27	25
ash flow from operations apex - maintenance	218	236	432	538	610
apex - new investment	(99)	(413)	(626)	(1,646)	(43
et acquisitions & disposals	(00)	-	(020)	-	(10
ther investments (net)	-	-	-	-	
ash flow from investing	(99)	(413)	(626)	(1,646)	(43
ividends paid	(101)	(263)	(184)	(268)	(303
quity finance	0	198	2,270	0	(
ebt finance	13	159	(15)	(15)	(15
ther financing cash flows	(21)	(1)	6	2	2
ash flow from financing	(109)	93	2,077	(281)	(317
on-recurring cash flows	-	-	-	-	
ther adjustments	0 0	0 0	0 0	0 0	(
et other adjustments ovement in cash	10	(84)	1,883		250
ree cash flow to firm (FCFF)	126.42	(167.40)	(180.57)	(1,389) (1,094.23)	579.47
ree cash flow to equity (FCFE)	111.42	(19.25)	(203.64)	(1,121.37)	552.92
		(((.,.=,	
er share (THB) CFF per share	0.48	(0.63)	(0.68)	(4.14)	2.19
CFE per share	0.40	(0.03)	(0.00)	(4.25)	2.09
ecurring cash flow per share	2.37	1.77	1.60	1.94	2.22
alance Sheet (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
angible fixed assets (gross)	288	483	722	797	812
ess: Accumulated depreciation	(55)	(59)	(63)	(68)	(74
angible fixed assets (net)	233	424	659	729	738
tangible fixed assets (net)	8	7	7	7	7
ong-term financial assets	8	8	8	8	8
vest. in associates & subsidiaries	0	0	188	1,773	1,812
ash & equivalents	182	98	1,980	591	841
/C receivable	3	5	5	6	7
iventories	26	63	66	76	85
ther current assets	131	166	301	288	277
urrent assets	342 9	331	2,353 188	961 222	1,210 252
ther assets otal assets	600	177 947	3,403	3,699	4,027
common equity	167	404	2,857	3,125	3,429
linorities etc.	0	0	2,007	0,120	0, 120
otal shareholders' equity	167	404	2,857	3,125	3,429
ong term debt	141	291	276	261	246
ther long-term liabilities	5	3	9	11	13
ong-term liabilities	145	294	286	272	259
/C payable	98	148	151	175	199
hort term debt	7	15	15	15	15
ther current liabilities	182	86	94	111	126
urrent liabilities	288	249	260	301	340
otal liabilities and shareholders' equity	600	947	3,403	3,699	4,027
et working capital	(121)	0	128	84	45
vested capital Includes convertibles and preferred stock which is being	138 utreated as debt	616	1,178	2,821	2,862
er share (THB)					
pok value per share	1.65	2.12	10.82	11.84	12.99
angible book value per share	1.57	2.09	10.80	11.81	12.96
nancial strength					
et debt/equity (%)	(20.2)	51.7	(59.1)	(10.1)	(16.9
et debt/total assets (%)	(5.6)	22.1	(49.6)	(8.5)	(14.4
urrent ratio (x)	1.2	1.3	9.1	3.2	3.6
interest cover (x)	31.4	44.1	31.2	39.0	46.7
luation	2021	2022	2023E	2024E	20255
ecurring P/E (x) *	36.0	36.6	41.7	28.6	25.
ecurring P/E @ target price (x) *	44.0	44.8	51.0	35.0	30.9
eported P/E (x)	36.0	36.6	41.7	28.6	25.2
ividend yield (%)	0.6	0.5	1.2	1.7	
rice/book (x)	35.2	27.3	5.4	4.9	4.5
	36.9	27.8	5.4	4.9	4.5
V/EBITDA (x) **	24.0	26.6	25.7	22.8	
rice/tangible book (x) V/EBITDA (x) ** V/EBITDA @ target price (x) ** V/invested capital (x)		26.6 32.5 18.2	25.7 32.2 11.6	22.8 28.0 5.3	19.6 24.2 5.7

Sources: Master Style; FSSIA estimates



Disclaimer for ESG scoring

ESG score	Methodolog	У			Rating				
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process base from the ann Only the top- inclusion.	ed on the com nual S&P Glob -ranked comp	transparent, rules-based panies' Total Sustainabi al Corporate Sustainabil anies within each industr	ility Scores resulting ity Assessment (CSA). ry are selected for	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Globa ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.				
Sustainability Investment List (<u>THSI</u>) by The Stock Exchange of Thailand (<u>SET</u>)	managing bu Candidates (1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the ar trading of th shareholders come key disque pendent direct related to CG,	ility in Environmental and ansparency in Governan preemptive criteria, with he board members and e s, and combined holding ualifying criteria include: tors and free float violati social & environmental earnings in red for > 3 yes	ace, updated annually. a two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	minimum of 50 during the asse nature of the re <u>SETTHSI Inde</u> capitalization > >0.5% of paid-I	% for each inc essment year. elevant industr <u>x</u> is extended THB5b (~US up capital for a et capitalisation	sion, verified dat licator, unless th The scoring will y and materiality from the THSI cc D150b); 2) free fl at least 9 out of 1 on-weighted inde mber of stocks.	e company is be fairly weigh ompanies who oat >20%; and 2 months. The	a part of DJSI ted against the se 1) market d 3) liquidity e SETTHSI
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	the Thai IOD,	h in sustainable develop with support from the Sto ts are from the perspecti s.	ock Exchange of	Good (80-89), and not rated for equitable treatr	3 for Good (70 or scores belo nent of shareh 25%); 4) disclo	ories: 5 for Excel -79), 2 for Fair (6 w 50. Weightings holders (weight 2 sure & transpare	60-69), 1 for P include: 1) th 5% combined	ass (60-69), e rights; 2) and); 3) the role of
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment an transparent a out of five th criteria cover date (45%), <i>circulation of s</i> <i>exercised. The</i> <i>and verifiability</i>	e incorporated and sufficiently e CG compon r AGM proced and after the r <i>ufficient informa</i> e second assess y; and 3) openne	which shareholders' right d into business operation y disclosed. All form imp- ients to be evaluated anr lures before the meeting meeting (10%). (The first a tion for voting; and 2) facilita es 1) the ease of attending n ses for Q&A. The third involve es, resolutions and voting re	is and information is ortant elements of two nually. The assessment (45%), at the meeting assesses 1) advance ting how voting rights can be meetings; 2) transparency es the meeting minutes that			o four categories: (80-89), and not		
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmen policies. The (Companies de Declaration of Certification, ir managers and	nt of key contr e Certification i eciding to becom Intent to kick off including risk ass	Checklist include corrupt rols, and the monitoring a is good for three years. If an 18-month deadline to sul essment, in place of policy a ablishment of whistleblowing II stakeholders.)	and developing of start by submitting a bmit the CAC Checklist for ind control, training of	passed Checkl	ist will move fo se members a	ed by a committe or granting certifi re twelve highly ichievements.	cation by the (CAC Council
<u>Morningstar</u> Sustainalytics	based on an risk is unmai regulatory filing	assessment on aged. Sources gs, news and other section of the sect	sk rating provides an ove of how much of a compa s to be reviewed include corp her media, NGO reports/web	ny's exposure to ESG porate publications and sites, multi-sector			score is the sum higher ESG risk Medium	is scored.	d risk. The Severe
		ompany teedbac uality & peer revi	k, ESG controversies, issuer iews.	feedback on draft ESG	NEGL Low Medium High Se 0-10 10-20 20-30 30-40 4				
ESG Book	positioned to the principle helps explain over-weightin	o outperform o of financial m n future risk-ad	sustainable companies the wer the long term. The m ateriality including inform djusted performance. Ma th higher materiality and erly basis.	nethodology considers nation that significantly ateriality is applied by	The total ESG scores using m	score is calcul ateriality-base	ated as a weight d weights. The s idicating better p	ed sum of the core is scaled	features
<u>MSCI</u>		0		anagement of financially their exposure to ESG ri					nethodology to
	AAA AA	8.571-10.00 7.143-8.570	Leader:	leading its industry in m	anaging the most s	ignificant ESG ri	sks and opportunitie	es	
	A 5.714-7.142 BBB 4.286-5.713 Average: a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative industry peers BB 2.857-4.285						nities relative to		
	B 1.429-2.856 CCC 0.000-1.428 Laggard: lagging its industry based on its high exposure and failure to manage significant ESG risks								
<u>Moody's ESG</u> solutions	believes that	t a company ir		take into account ESG on to its business model an medium to long term.					
Refinitiv ESG rating	based on pu	blicly available	e and auditable data. The	e a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performar	nce and insufficie	nt degree of t	
S&P Global				asuring a company's perf ssification. The score ran			of ESG risks, op	portunities, ar	d impacts
	ESG Score	<u> </u>	Bloomberg score evalu	ating the company's agg	regated Environn	nental, Social			
Bloomberg			score is based on Bloo of Pillar Scores, where	the weights are determin					

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

FINANSIA

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Sureeporn Teewasuwet FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Sureeporn Teewasuwet started covering this stock from 12-Dec-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Master Style	MASTER TB	THB 58.00	BUY	Downside risks to our P/E-based TP include 1) increased competition, 2) a pandemic that results in a lockdown, 3) lower-than-expected utilization rate of new operating beds, 4) higher-than-expected doctor costs and expenses, and 5) a loss contribution from the acquired units.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 2-Jan-2024 unless otherwise stated.



RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

